<DOC>
	<DOCNO>NCT00775840</DOCNO>
	<brief_summary>The purpose study determine effect candesartan , daily ( QD ) , N-terminal pro-B-type Natriuretic Peptide laboratory marker subject symptomatic heart failure diastolic dysfunction .</brief_summary>
	<brief_title>Efficacy Candesartan Symptomatic Heart Failure Treating Diabetic Hypertensive Patients .</brief_title>
	<detailed_description>Heart diseases number one cause death develop country particular chronic congestive heart failure lead cause hospitalization patient older 65 year . It still increase prevalence , spite significant advance therapy , mortality rate remain high : 30 % 40 % patient advanced disease , 5 % 10 % patient mild symptom die within 5 10 year . A relevant proportion heart failure patient ( 30 - 50 % ) suffering edema dyspnea normal minimally impaired leave ventricular ejection fraction ( preserve left ventricular ejection fraction ) diastolic abnormality echocardiography . Features diastolic dysfunction stiffness , decrease compliance impaired relaxation leave ventricle . As result , leave ventricle limited filling capacity normal leave atrial pressure . Hypertension and/or diabetes predispose condition whereas leave ventricular hypertrophy regard link intermediate pathological condition . Moreover , recent study show patient symptomatic heart failure ejection fraction great 40 % poor prognosis relatively high mortality hospitalization rate . Thus , hypertensive patient , diastolic dysfunction show predictor morbidity . Diastolic dysfunction also frequent find type 2 diabetes without symptom sign heart disease . As long independent ischemic heart disease , presumably due diabetic cardiomyopathy . Once aggravated heart failure , diastolic dysfunction often coexist systolic dysfunction consequence coronary artery disease limit coronary reserve . This study determine whether pharmacological intervention Renin Angiotensin Aldosterone System exert Angiotensin-Receptor Blocker Candesartan top Angiotensin-Converting Enzyme Inhibitor-based therapy may lead significant drop N-terminal pro-B-type Natriuretic Peptide . This neurohormonal laboratory marker sufficient enough simultaneously indicate improvement cause diastolic dysfunction associate heart failure symptom assess objective echocardiographic clinical parameter . Total time participant study approximately 26 week .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<criteria>Diabetes mellitus type 2 insulin dependent orally treat manage diet least 3 Months . Normotension control hypertension sit Systolic Blood Pressure less 140 mmHg and/or sit Diastolic Blood Pressure less 90 mmHg . Regular sinus rhythm atrial fibrillation medicamentalachieved rate control le 100 bpm confirm electrocardiogram recording . Echocardiographic evidence preserve Left Ventricular Ejection Fraction great equal 45 % ( assess modify Simpson method ) , dopplerechocardiographic criterion diastolic dysfunction grade IIV . New York Heart Association classification II III stable condition since least 3 month . Existing background heart failure therapy AngiotensinConverting Enzyme Inhibitor alone together preparation constant regimen since least 1 month , case betablockers since least 3 month . Nterminal proBtype Natriuretic Peptide great equal 250 pg/ml measure screen visit collect date previous laboratory document old 3 month . No previous therapy AngiotensinReceptor Blockers last 4 week prior study . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Impaired renal function ( serum creatinine great 2.2 mg/dl great 194 Î¼mol/l ) . Known bilateral renal artery stenosis interventional treatment renal artery stenosis last year . State kidney transplantation . Serum potassium great 5.5 mmol/l glycosylated hemoglobin great 9.5 % . Cor pulmonale primary pulmonary disease dyspnea rest . Known disposition episodes symptomatic hypotension sit Systolic Blood Pressure less 95 mmHg baseline . Acute coronary syndrome form unstable chronic Coronary Artery Disease indication coronary intervention either plan short medium term clearly exclude period study . Any history : myocardial infarction , previous Percutaneous Transluminal Coronary Angioplasty revascularization , stent implantation , Coronary Artery Bypass Graft open heart surgery . Tachycardia rest great 100 bpm confirm electrocardiogram recording . Known clinically relevant rhythm disorder ( e.g. , tachyarrhythmias , salve supraventricular ventricular extrasystole atrial fibrillation without ventricular rate control ) symptom suggest significant rhythm disorder ( e.g. , recurrent syncope ) . Primary valvular disease and/or restrictive obstructive cardiomyopathy . Existing ventricular assist device . Relevant liver disease ( cholestasis alanine aminotransferase/aspartate aminotransferase great 2 time upper limit normal gamma glutamyltransferase great 3 time upper limit normal ) . History primary hyperaldosteronism , cancer last 5 year another wasting disease life expectancy le 2 year . Known hypersensitivity Candesartan Cilexetil . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Need maintenance therapy Nonsteroidal antiinflammatory drug Cox2inhibitors . Use AngiotensinReceptor Blockers . Any history lifethreatening disease . History drug addiction and/or extensive use alcohol . Acute coronary syndrome unstable angina pectoris coronary artery disease stable last 3 month prior inclusion . Patients dependent permanently pace pacemaker ( i.e . patient device pace echocardiographic examination enter study ) . Open heart surgery reason coronary revascularization Participation another clinical investigation within 30 day prior enrolment course present study .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Cardiac Failure</keyword>
	<keyword>Congestive Heart Failure</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Diabetes Mellitus</keyword>
</DOC>